EU Approves AstraZeneca’s Enhertu for Early HER2-Positive Breast Cancer
The European Commission approved Enhertu as an adjuvant monotherapy for HER2-positive early breast cancer.
The European Commission approved Enhertu as an adjuvant monotherapy for HER2-positive early breast cancer.